Medical management of chronic obstructive pulmonary disease (Q35610397)

9 August 2017

1 reference

title

Medical management of chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

9 August 2017

main subject

1 reference

Frank C Sciurba

1

0 references

publication date

1 November 2003

1 reference

Chest surgery clinics of North America

9 August 2017

published in

1 reference

9 August 2017

volume

13

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

615-629

1 reference

The global burden of disease, 1990–2020

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Accuracy of history, wheezing, and forced expiratory time in the diagnosis of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

The value of the forced expiratory time in the physical diagnosis of obstructive airways disease.

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Standardization of Spirometry, 1994 Update. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

The utility of spirometry in the diagnosis of reversible airways obstruction

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

The diffusing capacity as a predictor of arterial oxygen desaturation during exercise in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

ATS/ACCP Statement on cardiopulmonary exercise testing

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Woodsmoke exposure and risk for obstructive airways disease among women

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD?

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Evaluation of bronchodilator responses in patients with "irreversible" emphysema

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Salmeterol Reduces Dyspnea and Improves Lung Function in Patients With COPD

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD.

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

The pendulum swings again. Toward a rational use of theophylline

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Additive effects of salmeterol and fluticasone or theophylline in COPD

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Salmeterol plus theophylline combination therapy in the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies.

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Differing effects of the anxiolytic agents buspirone and diazepam on control of breathing.

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

New treatments for COPD.

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Rationale and design of the national emphysema treatment trial (NETT): A prospective randomized trial of lung volume reduction surgery

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Altered exercise gas exchange and cardiac function in patients with mild chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Long-term effects of outpatient rehabilitation of COPD: A randomized trial

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Quality of life in acute exacerbation of chronic bronchitis: results from a German population study

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Controlled trial of oral prednisone in outpatients with acute COPD exacerbation

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Relationship Between Bacterial Flora in Sputum and Functional Impairment in Patients With Acute Exacerbations of COPD

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

The spectrum of acute bronchitis. Using baseline factors to guide empirical therapy

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016/S1052-3359(03)50099-1

7 January 2021

10.1016/S1052-3359(03)00099-1

Identifiers

DOI

1 reference

9 August 2017

1 reference